Skip to main content

Table 3 Clinical classification of severity in GATPC

From: Comparison of heat-sensitive moxibustion versus fluticasone/salmeterol (seretide) combination in the treatment of chronic persistent asthma: design of a multicenter randomized controlled trial

Characteristic

Intermittent (Grade I)

Mild (Grade II)

Moderate (Grade III)

Severe (Grade IV)

symptoms

Less than once week

More than once week, < once a day

Everyday

Everyday

Limitation of activities and sleep

Transient

May be affect activities and sleep

Affect activities and sleep

Frequent

Nocturnal of symptoms/awakening

Less than twice a month

More than twice a month, < once a week

More than once week

Frequent

Lung function(PEF or FEV1)

≥80% predicted (FEV1)or personal best (PEF); mutation rate < 20%

≥80% predicted (FEV1)or personal best (PEF); mutation rate 20%~30%

60%~79% predicted (FEV1)or personal best (PEF); mutation rate > 30%

< 60% predicted (FEV1)or personal best (PEF); mutation rate > 30%